ClinicalTrials.gg
RecruitingNCT04162353Updated Sep 16, 2025

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

A Phase 1 interventional study of BCMA-CD19 cCAR T cells in Multiple Myeloma in Relapse, Refractory Multiple Myeloma and Plasmacytoid; Lymphoma, sponsored by iCell Gene Therapeutics. Recruiting at 2 sites in China. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by iCell Gene Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jul 2019, registered Nov 2019).
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
345th of 406
12 · median 40
Started
2019
with 32 others
Phase 1
151 of 448
73 open now
Primary completion
2026-07
later than 92 of 274 live
Registered
91st of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 345th largest by planned enrollment of the 406 interventional ones that give a count, is one of 33 that started in 2019, is one of 151 in phase 1, reaches primary completion later than 92 of the 274 other live ones, and was the 91st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.

Read the detailed description

BCMA-CD19 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressing on a T-cell, directed against the surface proteins BCMA and CD19. BCMA-CD19 cCAR is also aimed to treat multiple myeloma, a challenging disease due to the heterogeneity of myeloma cells, which renders single-antigen targeting CAR T-cell therapy ineffective. BCMA-CD19 cCAR is proposed to target both bulky myeloma cells expressing BCMA, and myeloma stem cells expressing CD19 to effectively eradicate the disease.

BCMA-CD19 cCAR is also aimed to treat heterogeneous plasmacytoid lymphoma bearing two types of lymphoma cells, regular lymphoma cells expressing CD19 and plasmacytoid lymphoma cells expressing BCMA. The use of two different targets intends to increase coverage and eradicate cancerous cells before resistance develops in surviving cancer cells that have undergone selective pressures or antigen escape.

03

Conditions studied

  • Multiple Myeloma in Relapse
  • Refractory Multiple Myeloma
  • Plasmacytoid; Lymphoma

Keywords

  • BCMA
  • CD19
  • BCMA-CD19 cCAR T cells
  • multiple myeloma
  • plasmacytoid lymphoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written ; Patients volunteer to participate in the research
  • Diagnosis is mainly based on the World Health Organization (WHO) 2008
  • Patients have exhausted standard therapeutic options
  • Systematic usage of drug or must have been stopped for more than 1 weeks
  • Female must be not pregnant during the study

Exclusion criteria

Exclusion Criteria:

  • Patients declining to consent for treatment
  • Prior solid organ transplantation
  • Potentially curative therapy including chemotherapy or hematopoietic cell transplant
  • Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    BCMA-CD19 cCAR

    Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg

    Biological: BCMA-CD19 cCAR T cells

Interventions

  • BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy

06

What researchers measure

Primary outcomes

  1. Number of adverse events after BCMA-CD19 cCAR T cells infusion

    Determine the toxicity profile of BCMA-CD19 cCAR T cell therapy

    Time frame: 2 years particularly the first 28 days after infusion

Secondary outcomes

  1. Incidence of treatment-emergent adverse events

    Incidence of treatment-emergent adverse events

    Time frame: up to 6 months

Other outcomes

  1. For multiple myeloma - Stringent complete response

    Stringent complete response (sCR) (IMWG criteria)

    Time frame: 24 months

  2. For multiple myeloma - Complete response (CR)

    Complete response (CR) (IMWG criteria)

    Time frame: 24 months

  3. For multiple myeloma - Very good partial response (VGPR)

    Very good partial response (VGPR) (IMWG criteria)

    Time frame: 24 months

  4. For multiple myeloma - Partial response (PR)

    Partial response (PR) (IMWG criteria)

    Time frame: 24 months

  5. For multiple myeloma - Minimal response (MR)

    Minimal response (MR) (IMWG criteria)

    Time frame: 24 months

  6. For multiple myeloma - Stable disease (SD)

    Stable disease (SD) (IMWG criteria)

    Time frame: 24 months

  7. For multiple myeloma - Progressive disease (PD)

    Progressive disease (PD) (IMWG criteria)

    Time frame: 12 months

  8. For multiple myeloma - Progression-free survival (PFS)

    Progression-free survival (PFS) (IMWG criteria)

    Time frame: up to 24 months

  9. For plasmacytoid lymphoma - Assessment of morphologic CR, CR1, no residual disease, and molecular remission

    Assessment of morphologic complete remission (CR), complete remission with incomplete recovery of counts (CR1), no residual disease as analyzed by flow cytometry analysis, and molecular remission by molecular studies

    Time frame: 1 year

  10. For plasmacytoid lymphoma - Progression-free survival (PFS)

    Progression-free survival (PFS)

    Time frame: 1 year

  11. For plasmacytoid lymphoma - Overall survival

    Overall survival

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Peking University Shenzhen Hospital, China
    Shenzhen, Guangdong, China
    Recruiting
  • Chengdu Military General Hospital
    Chengdu, Sichuan, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Jul 2026, 84 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 84 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2019
First posted
Nov 14, 2019
StartActual
Jul 1, 2019
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04162353
Lead sponsor
iCell Gene Therapeutics
Collaborators
iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital
Responsible party
Sponsor
First posted
Nov 14, 2019
Start date
Jul 1, 2019
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Sep 16, 2025

Study contacts

Kevin Pinz, MS
Contact
kevin.pinz@icellgene.com
6315386218
Hongyu Zhang, MD/PhD
principal investigator · Peking University Shenzhen Hospital, China
Fang Liu, MD/PhD
principal investigator · Chengdu Military General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCMA-CD19 Compound CAR T Cells

Start the discussion